## CHRW: C.H. Robinson Worldwide, Inc. - XLI: Industrials

### Executive Summary

No thesis match: MRS_20 -3.5% below STRENGTH zone (4.0-10.0%); PEG 2.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($145.28)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Russell Investments Group Ltd. Cuts Stake in C.H. Robinson Worldwide, Inc. $CHRW**
- Source: MarketBeat | 20251207T100758 | Neutral | Relevance: 99%
-  Russell Investments Group Ltd. significantly reduced its holdings in C.H. Robinson Worldwide, Inc. by 37.7% in Q2, selling 26,635 shares but still retaining 44,013 shares valued at approximately $4.23 million. This comes as the company reported a Q3 EPS beat of $1.40 against an estimated $1.29, despite a 10.9% year-over-year revenue decline, and raised its quarterly dividend to $0.63. Analysts currently maintain a "Moderate Buy" consensus with an average price target of $143.

**2. Invesco Ltd. Has $230.56 Million Holdings in C.H. Robinson Worldwide, Inc. $CHRW**
- Source: MarketBeat | 20251208T110815 | Bullish | Relevance: 99%
-  Invesco Ltd. significantly increased its stake in C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) by 5.1% in the second quarter, bringing its total holdings to $230.56 million. Other institutional investors also adjusted their positions in the transportation company. Analysts have issued "buy" and "outperform" ratings for CHRW, with a consensus target price of $143.00.

**3. Rivulet Capital LLC Has $15.65 Million Holdings in Rxo Inc $RXO**
- Source: MarketBeat | 20251208T120931 | Neutral | Relevance: 64%
- Rivulet Capital LLC increased its stake in Rxo Inc (NYSE:RXO) by 32.8% in Q2, with institutional investors now owning 92.73% of the company. Company insiders have also been buying shares, accumulating 40,250 shares in the last 90 days. Despite mixed analyst ratings and an average price target of $16.69, RXO missed its latest quarterly EPS and slightly missed revenue, although it showed a 34.6% year-over-year revenue increase.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $85 | $77 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 4 ($1.86M) |
| Sells | 2 ($0.38M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (-3.0%)
- First Eagle Investme: 8.9% (-0.2%)
- Blackrock Inc.: 8.2% (-8.5%)
- Wellington Managemen: 6.1% (+198.6%)
- State Street Corpora: 5.8% (-7.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.9% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.16 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Analyst sentiment positive (1 raises, avg +10%). Insider buying signal ($1.9M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.0B |
| Beta | 0.91 |
| 52W Range | $84.68 - $162.79 |
| Short Interest | 7.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.16 |
| Forward P/E | 25.5 |
| Current P/E | 30.6 |
| YoY Growth | 19.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.4% to -3.5% (-4.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.5pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.34x) but short-term weakness (below SMA20). MACD histogram bearish (-1.09), momentum weakening. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.49% (CS: 30) | Weak |
| RSI_14 | 51.6 | Neutral |
| MACD Histogram | -1.09 | Bearish |
| vs SMA20 | 0.986x | Below |
| vs SMA50 | 1.065x | Above |
| vs SMA200 | 1.336x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $152.52
- **Stop Loss:** $145.28 (4.7% risk)
- **Target:** $159.76 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 69
- **Position Value:** $10,523.88
- **Portfolio %:** 10.52%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-28 (Est: $1.13)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.40 | +7.4% |
| 2025Q2 | $1.16 | $1.29 | +11.6% |
| 2025Q1 | $1.05 | $1.17 | +11.4% |
| 2024Q4 | $1.11 | $1.21 | +9.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*